Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles

Open Access

Original Article

Pharmacokinetics of combination antiparasitic drug preparation for dogs and cats in the form of spot-on solution

Mikhail Vladimirovich Arisov, Evgenia Nikolaevna Indyuhova, Gulnara Bakitovna Arisova.

Objective: The object of the study was to examine the major pharmacokinetic parameters after a single application of a complex drug preparation for veterinary use based on fipronil, praziquantel, moxidectin, and pyriproxyfen in cats and dogs.
Materials and Methods: For dogs, the drug preparation was administered spot-on solution in the following dosage of active pharmaceutical substances: fipronil 27.0 mg/kg body weight (bwt), praziquantel 10.8 mg/kg bwt, moxidectin 6.75 mg/kg bwt, and pyriproxyfen 5.4 mg/kg bwt; for cats, the dosage was the following: fipronil 43.2 mg/kg bwt, praziquantel 17.28 mg/kg bwt, mox-idectin 4.32 mg/kg bwt, and pyriproxyfen 8.64 mg/kg bwt. The blood samples were taken from dogs and cats. The principle of the method for determining praziquantel, trans-4-hydroxyprazi-quantel, pyriproxyfen, and fipronil in serum samples was chromatographed in a high-pressure liquid chromatograph with detection by means of a mass-spectrometric detector. The moxidectin content of the blood was detected by high-performance liquid chromatography.
Results: The drug preparation active substances: praziquantel, fipronil, and moxidectin are absorbed into the blood of dogs and cats. The penetration of praziquantel into the systemic circulation and further into organs and tissues was proved. After topical administration, moxidectin is absorbed and distributed systemically and is slowly removed from the plasma, which manifests itself in detectable concentrations of moxidectin in the blood for 1 month.
Conclusion: The present results of pharmacokinetic investigations may promote to the determination of effective therapy strategy and prophylaxis of parasitic diseases in dogs and cats.

Key words: Fipronil; moxidectin; pharmacokinetics; praziquantel; pyriproxyfen

Similar Articles

Potential neuroprotection by nobile Lindl alkaloid in Alzheimer's disease models.
Li DD, Zheng CQ, Zhang F, Shi JS
Neural regeneration research. 2022; 17(5): 972-977

Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma.
Shi Y, Zhang Q, Han X, Qin Y, Ke X, Su H, Liu L, Fu J, Jin J, Feng J, Hong X, Zhang X, Wu D, Jiang B, Dong X
Chinese journal of cancer research = Chung-kuo yen cheng yen chiu. 2021; 33(3): 405-416

A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers.
Sinn A, Garcia-Alvarado F, Gonzalez V, Huerga C, Bullo F
British journal of clinical pharmacology. 2021; ():

Influence of and Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans.
Park JW, Kim KA, Kim JM, Park IH, Park JY
Frontiers in pharmacology. 2021; 12(): 736317

N-(anilinoethyl)amide melatonergic ligands with improved water solubility and metabolic stability.
Ferlenghi F, Mari M, Gobbi G, Elisi GM, Mor M, Rivara S, Vacondio F, Bartolucci S, Bedini A, Fanini F, Spadoni G
ChemMedChem. 2021; ():

Full-text options

Latest Statistics about COVID-19
• pubstat.org

Add your Article(s) to Indexes
• citeindex.org

Covid-19 Trends and Statistics
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.

ScopeMed Web Sites